StockData

Caribou Biosciences vs Innate Pharma

CRBU and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRBU and IPHA compare

Caribou Biosciences grew revenue faster over the last twelve months (10.0% versus −55.2% for Innate Pharma).

Caribou Biosciences scores higher on the StockData Score (9 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRBUIPHA
Size and price
Market cap$36.5M–
Share price$0.341$1.33
Change, 1 year−82.9%−26.9%
Change, 5 years−98.1%−72.3%
Beta (5Y)1.411.28
Employees97181
StockData Score
Total score9 (better)0
Valuation score3 (better)0
Growth score1 (better)0
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S3.6×–
P/B0.4×–
FCF yield−262%–
Fair value$1.29–
Margin of safety73.7%–
Growth
Revenue growth (TTM)10.0% (better)−55.2%
Revenue growth, 5Y average−2.0% (better)−33.6%
Profitability
Operating margin−1091%−600% (better)
Net margin−1030%–
FCF margin−954%−587% (better)
Return on equity−78.3%–
Financial health
Debt / equity0.00–
Interest coverage–−17.3×
Current ratio6.49 (better)0.60
Altman Z-score−7.47–
Piotroski F-score2–
Dividends and buybacks
Buyback yield−66.3%–
Shareholder yield−66.3%–
Ownership
Held by institutions45.5%0.21%
Held by insiders5.7%16.2%
Insider net buying, 12 months−$47.5K–
Short interest, % of float14.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.